Dr. Reddys Labs (RDY) Reports Q4 EPS of $0.07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Dr. Reddy’s Q4 and FY16 Financial Results
May 12, 2016 6:47 AM EDT
Q4 Revenues at Rs. 37.6 billion
(YoY decline of 3%)
Q4 EBITDA at Rs. 4.8 billion
(12.8% of the revenues)
Q4 Adjusted EBITDA* at Rs. 9.0 billion
(24.0% of the
revenues)
FY16 Revenues at Rs. 154.7 billion
(YoY growth of 4%)
FY16 EBITDA at Rs. 36.3 billion
(23.4% of the revenues)
FY16 Adjusted EBITDA* at Rs. 41.2 billion
(26.7% of the
revenues)
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddys Laboratories Ltd. (NYSE: RDY | BSE: 500124 | NSE:... More
